MicroPort Scientific Corporation (MSK) - Total Liabilities
Based on the latest financial reports, MicroPort Scientific Corporation (MSK) has total liabilities worth €2.20 Billion EUR (≈ $2.57 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MicroPort Scientific Corporation - Total Liabilities Trend (2013–2025)
This chart illustrates how MicroPort Scientific Corporation's total liabilities have evolved over time, based on quarterly financial data. See MSK current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
MicroPort Scientific Corporation Competitors by Total Liabilities
The table below lists competitors of MicroPort Scientific Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Realia
MC:RLIA
|
Spain | €1.34 Billion |
|
Jinzhou Jixiang Molybdenum Co Ltd
SHG:603399
|
China | CN¥1.85 Billion |
|
Shipping Corporation Of India Limited
NSE:SCI
|
India | Rs43.78 Billion |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
USA | $369.03 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €119.06 Million |
|
China Railway Construction Corporation Limited
F:4FF
|
Germany | €1.70 Trillion |
|
Taiji Computer Corp Ltd
SHE:002368
|
China | CN¥10.85 Billion |
|
Anupam Rasayan India Limited
NSE:ANURAS
|
India | Rs22.01 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down MicroPort Scientific Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MSK market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MicroPort Scientific Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MicroPort Scientific Corporation (2013–2025)
The table below shows the annual total liabilities of MicroPort Scientific Corporation from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.20 Billion ≈ $2.57 Billion |
-11.74% |
| 2024-12-31 | €2.49 Billion ≈ $2.91 Billion |
-1.61% |
| 2023-12-31 | €2.53 Billion ≈ $2.96 Billion |
+14.90% |
| 2022-12-31 | €2.20 Billion ≈ $2.57 Billion |
+1.77% |
| 2021-12-31 | €2.16 Billion ≈ $2.53 Billion |
+100.06% |
| 2020-12-31 | €1.08 Billion ≈ $1.26 Billion |
+14.53% |
| 2019-12-31 | €943.99 Million ≈ $1.10 Billion |
+26.62% |
| 2018-12-31 | €745.50 Million ≈ $871.57 Million |
+60.61% |
| 2017-12-31 | €464.17 Million ≈ $542.66 Million |
+8.43% |
| 2016-12-31 | €428.07 Million ≈ $500.46 Million |
+2.95% |
| 2015-12-31 | €415.81 Million ≈ $486.13 Million |
-30.23% |
| 2014-12-31 | €595.99 Million ≈ $696.78 Million |
+364.12% |
| 2013-12-31 | €128.41 Million ≈ $150.13 Million |
-- |
About MicroPort Scientific Corporation
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, the United States of America, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; an… Read more